Condition: Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
An international, multicenter, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of GenSci145, as monotherapy or in combination therapy, in participants with PIK3CA-mutated, locally advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Binhe Xu · +8613501028690 · xubingheBM@163.com
Always discuss trial participation with your own doctor first.
| The Cancer Hospital of the Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07407504